Phase I-II Study of Carfilzomib, Lenalidomide, Dexamethasone, and Panobinostat, Ca-R-Pa-Diem, as Induction Therapy for Newly Diagnosed, Untreated, Transplant-Eligible, Multiple Myeloma Patients

Trial Profile

Phase I-II Study of Carfilzomib, Lenalidomide, Dexamethasone, and Panobinostat, Ca-R-Pa-Diem, as Induction Therapy for Newly Diagnosed, Untreated, Transplant-Eligible, Multiple Myeloma Patients

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Panobinostat (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Apr 2017 Planned End Date changed from 31 Dec 2020 to 1 Dec 2020.
    • 24 Apr 2017 Planned primary completion date changed from 30 Sep 2020 to 1 Sep 2020.
    • 24 Apr 2017 Planned initiation date changed from 30 Jun 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top